[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoplasms-colorectal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoplasms-colorectal":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100609363","phase-1-a-study-to-investigate-the-safety-and-preliminary-efficacy-of-gsk5460025-alone-or-in-combination-with-other-anti-cancer-agents-in-participants-with-solid-tumors-100609363",false,"NCT07213609","A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","A Phase 1\u002F2 Open-label, Multicenter Study of Oral GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors","Inclusion Criteria:\n\n* Has a histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor\n* Has a known dMMR\u002FMSI-H status as determined by a certified local laboratory at the time of Pre-screening or has an unknown Mismatch repair (MMR)\u002F Microsatellite Instability (MSI) status at the time of Pre-screening and MMR\u002FMSI status will be determined by central reference laboratory\n* Provides an archival or fresh (preferred) formalin fixed, paraffin embedded (FFPE) sample\n* Intends to receive GSK5460025 as next treatment\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Is expected to have a minimum of 3 months life expectancy\n* Has adequate organ function, as defined in the protocol\n\nPart 1 inclusion criteria:\n\n• Has histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor and has exhausted all standard of care treatment options\n\nPart 2 inclusion criteria:\n\n* Has histologically diagnosed advanced (unresectable, metastatic or recurrent) Colorectal cancer (CRC) or Endometrial cancer (EC)\n* Has received at least 1 but no more than 3 lines of systemic anticancer therapy for their advanced (unresectable, metastatic or recurrent) disease including at least one line of Immune checkpoint inhibitors (ICI) therapy\n* Has measurable disease (i.e., at least 1 target lesion) during the Screening period per RECIST 1.1, as determined by the investigator\n\nExclusion Criteria:\n\n* Has not recovered (i.e., to Grade ≤1 or to baseline) from prior anticancer therapy-induced Adverse Events (AEs)\n* Has received prior treatment with a Werner (WRN) inhibitor or Nucleotide Excision Repair Targeting (NERT) agent.\n* Is unable to swallow and retain orally administered study treatment\n* Has untreated or progressed metastases in brain or CNS\n* Has a known additional malignancy that progressed or required active treatment within the last 2 years because reoccurrence of another malignancy would confound interpretation by RECIST 1.1 criteria. Exceptions include basal or squamous cell carcinomas of the skin or in situ carcinomas \\[e.g., breast, cervix, bladder\\] that have been resected with no evidence of metastatic disease.\n* Has any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drugs\n* Has cirrhosis or current unstable liver or biliary disease\n* Has known hypersensitivity to any of the study interventions or any of their excipients","ALL","18 Years",{"count":19,"type":20},47,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.",[27,28],"Neoplasms, Colorectal","Neoplasms",[30,31,32,33,34,35,36,37,38,39],"GSK5460025","Solid tumors","Colon cancer","Rectal cancer","Colorectal cancer","Endometrial cancer","Mismatch repair deficient","dMMR","microsatellite instability high","MSI-H","RECRUITING","2026-06-17",{"date":43,"type":44},"2026-06-18","ACTUAL",{"date":46,"type":44},"2025-10-20",{"date":48,"type":20},"2028-10-27",{"name":50,"class":51},"GlaxoSmithKline","INDUSTRY",19,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":64,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100408050","endoscopic-mucosal-resection-versus-endoscopic-submucosal-dissection-for-colorectal-laterally-spreading-lesions-100408050","NCT04593407","Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions.","Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Laterally Spreading Lesions Non Granular-Flat Elevated Type (LSL-NG-FE) ≥ 20 mm and LSLs-Granular Mixed Type ≥ 30 mm. A Randomized, Non-inferiority Trial.","intERsection","Inclusion Criteria:\n\n* Adults (at least 18 years old).\n* LSL-NG FE type ≥ 20mm or LST-G mixed type ≥30mm who have not been previously treated or received submucosal injection, regardless of their location in the colon.\n* LSL-NG FE type ≥ 20mm or LST-G mixed type ≥30mm WITHOUT a demarcated area\n* The patient must have undergone a complete colonoscopy, reaching the cecum, to detect possible synchronous lesion. If this procedure has not been done previously, it will be performed prior to the inclusion of the patient in the study.\n* Patients able to fill in questionnaires written in Spanish or English.\n\nExclusion Criteria:\n\n* Contra-indication to colonoscopy.\n* Contra-indication to general anesthesia.\n* Inability to stop antiplatelet agents and anti-coagulant according to the European Society of Gastro-Intestinal Endoscopy guidelines.\n* Patients with \\> 1 lesion meeting the inclusion criteria.\n* LSL-NG FE type ≥ 20mm or LST-G ≥30mm mixed type that have been previously treated (Recurrence or residual lesion after previous endoscopic or surgical treatment).\n* LSL-NG FE type ≥ 20mm or LST-G ≥30mm mixed type with previous submucosal injection, even if a resection attempt with a snare was not finally performed.\n* Lesions with suspicion of deep submucosal invasive carcinoma: depression or invasive pit-pattern (Vi within a demarcated area or Vn).\n* Submucosal mass like elevation within a LSL-NG FE type.\n* LSLs having a previous biopsy or tattooing. Previous biopsies of the lesion should only be allowed if LSL-G mixed type \\> 30 mm and samples were taken out of the flat area.\n* LSL-G with a Buddha like deformation (Polyp on polyp)\n* LSL involving a surgical anastomosis.\n* LSL involving the appendicular orifice.\n* LSL involving the terminal ileum.\n* Patient's refusal to participate in the study\n* Presence of inflammatory bowel disease\n* Pregnant or lactating women.\n* Hereditary colorectal cancer syndrome or hereditary polyposis.\n* Patient under legal protection and or deprived of liberty by judicial or administrative decision.\n* Patient already participating in an interventional clinical research protocol\n* Patient who cannot be followed for the duration of the study.\n* Inability to sign the informed consent of the study.","85 Years",{"count":63,"type":20},376,[65],"NA","EMR and ESD are both effective and safe and are associated with a very low risk of procedure related mortality when performed for colorectal laterally spreading lesions (LSL).\n\nSome kind of LSLs have a low risk of submucosal invasive carcinoma (SMIC) or these foci are found in well demarcated areas of the tumor. This is the case of the non-granular flat elevated (LSN-NG-FE) and the LSLs-G mixed subtypes.\n\nThe investigators aim to assess if piecemeal EMR (the older technique) for LSLs-G mixed type \\> 30 mm and LSLs-NG FE type \\> 20 mm is not inferior to ESD (the new treatment) for the need of additional surgery in the mid-term.",[27],[69,70,71,72,73,74,75,76,77,78,28,79],"Colonic Polyps","large laterally spreading lesion","colonic adenoma","Endoscopic submucosal dissection","Endoscopic Mucosal Resection","Adenoma","Polyps","Pathological Conditions, Anatomical","Neoplasms, Glandular and Epithelial","Neoplasms by Histologic Type","Intestinal Polyps","2025-03-11",{"date":82,"type":44},"2025-03-13",{"date":84,"type":44},"2020-11-03",{"date":86,"type":20},"2026-12-30",{"name":88,"class":89},"José Carlos Marín Gabriel","OTHER",1]